Jonathan Chang
Stock Analyst at Leerink Partners
(3.89)
# 1,925
Out of 5,125 analysts
554
Total ratings
35.6%
Success rate
5.4%
Average return
Main Sectors:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Reiterated: Buy | $2 → $31 | $21.62 | +43.39% | 49 | Oct 29, 2026 | |
| WHWK Whitehawk Therapeutics | Initiated Coverage: Buy | $9 | $3.13 | +187.54% | 1 | Jul 13, 2026 | |
| MOLN Molecular Partners AG | Reiterated: Buy | n/a | $3.14 | - | 7 | Jun 2, 2026 | |
| CMPX Compass Therapeutics | Reiterated: Buy | $11 | $0.7588 | +1,349.66% | 1 | Apr 27, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $67 → $147 | $192.28 | -23.55% | 40 | Apr 13, 2026 | |
| NBTX Nanobiotix | Reiterated: Buy | $24 → $37 | $30.63 | +20.80% | 17 | Apr 1, 2026 | |
| IMTX Immatics | Reiterated: Buy | $17 | $6.36 | +167.30% | 44 | Mar 6, 2026 | |
| AKTS Aktis Oncology | Initiated Coverage: Buy | $31 | $15.82 | +95.95% | 1 | Feb 3, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $20 | $7.27 | +175.10% | 51 | Jan 13, 2026 | |
| NVCR NovoCure | Reiterated: Buy | $33 → $24 | $13.28 | +80.72% | 19 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $74 | $25.48 | n/a | 51 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 → $39 | $53.63 | n/a | 45 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $8 → $6 | $0.0549 | n/a | 36 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $5 | $2.33 | n/a | 38 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $0.11 → $0.09 | $0.0199 | n/a | 38 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $3.61 | n/a | 30 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $30.99 | n/a | 13 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 | $35.75 | n/a | 32 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.015 | n/a | 23 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $927.21 | n/a | 1 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $35.41 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $18 → $2 | $0.0001 | n/a | 15 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.10 | n/a | 1 | Jun 1, 2022 |
Replimune Group
Oct 29, 2026
Reiterated: Buy
Price Target: $2 → $31
Current: $21.62
Upside: +43.39%
Whitehawk Therapeutics
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $3.13
Upside: +187.54%
Molecular Partners AG
Jun 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.14
Upside: -
Compass Therapeutics
Apr 27, 2026
Reiterated: Buy
Price Target: $11
Current: $0.7588
Upside: +1,349.66%
Revolution Medicines
Apr 13, 2026
Reiterated: Buy
Price Target: $67 → $147
Current: $192.28
Upside: -23.55%
Nanobiotix
Apr 1, 2026
Reiterated: Buy
Price Target: $24 → $37
Current: $30.63
Upside: +20.80%
Immatics
Mar 6, 2026
Reiterated: Buy
Price Target: $17
Current: $6.36
Upside: +167.30%
Aktis Oncology
Feb 3, 2026
Initiated Coverage: Buy
Price Target: $31
Current: $15.82
Upside: +95.95%
Kura Oncology
Jan 13, 2026
Reiterated: Buy
Price Target: $20
Current: $7.27
Upside: +175.10%
NovoCure
Jan 13, 2026
Reiterated: Buy
Price Target: $33 → $24
Current: $13.28
Upside: +80.72%
Oct 21, 2025
Reiterated: Buy
Price Target: $74
Current: $25.48
Upside: n/a
Oct 13, 2025
Reiterated: Buy
Price Target: $34 → $39
Current: $53.63
Upside: n/a
Oct 10, 2025
Reiterated: Hold
Price Target: $8 → $6
Current: $0.0549
Upside: n/a
Aug 18, 2025
Reiterated: Buy
Price Target: $8 → $5
Current: $2.33
Upside: n/a
Aug 13, 2025
Reiterated: Hold
Price Target: $0.11 → $0.09
Current: $0.0199
Upside: n/a
Aug 11, 2025
Reiterated: Buy
Price Target: $24
Current: $3.61
Upside: n/a
Aug 11, 2025
Reiterated: Buy
Price Target: $60
Current: $30.99
Upside: n/a
Aug 7, 2025
Reiterated: Buy
Price Target: $27
Current: $35.75
Upside: n/a
Nov 12, 2024
Reiterated: Buy
Price Target: $2
Current: $0.015
Upside: n/a
Jun 30, 2023
Reiterated: Buy
Price Target: n/a
Current: $927.21
Upside: n/a
Jan 11, 2023
Rated: Buy
Price Target: n/a
Current: $35.41
Upside: n/a
Nov 14, 2022
Downgraded: Hold
Price Target: $18 → $2
Current: $0.0001
Upside: n/a
Jun 1, 2022
Reiterated: Buy
Price Target: n/a
Current: $3.10
Upside: n/a